RE:RE:So...Scorpio2 wrote: You got that right.
Despite how much we all puked on that management decision, Theralase management are very lucky (alongside all shareholders) that the decision to finance was made at that time. I don't give management any credit to have foreseen the onset of a black swan like CV but I think they saw that their backs were against the wall and they had no options but to strike some sort of deal at the time they did, $hitty as it was. Personal survival was the motivating factor for management and all their high salaries. Let's just call the timing of the financing as being extremely lucky in context to today. Sometimes it's better to be lucky than smart and that is what has happened here. In my personal estimation, if this financing had not been made at the time they did, Theralase likely would have gone under with no ability to finance the company or the Phase 2 trial in this "new normal" CV financial environment.
Now that Theralase management have been lucky enough to have been dealt "two pair" in this game of financial poker due to the financing, their/our chances of success are high but they will need to execute flawlessly going forward to win the pot.
We've already played the scientific 5 year poker game flawlessly.. Flop, Turn and River (Early Phase 1b approval)
Now Phase 2 we show our hands with 2nd treatments and some 90 day becuase we know darn well the statistics for Photofrin with Bladder cancer is really high...... there is so much established science of high CR on the back of 'unoptimized' science in the 90's i.e. Red light with no way to measure the refractory light as 'overdosing' that sigh.. I believe Photofrin got over 60% if not higher..
I question what is meant by 'Clinically Relevant'
Does anyone really think that if we are 9/10 at 3 months with P1 and P2 showing safety at 2nd treatment, that wouldn't get us to our target .80 USD?
You have drugs that test 50 patients that have a 20% CR so 1:5 and get massive biotech pops.
It's really getting sickening TBH....